GQG Partners LLC Acquires Shares of 96,264 Bristol Myers Squibb Company $BMY

GQG Partners LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 96,264 shares of the biopharmaceutical company’s stock, valued at approximately $5,547,000.

A number of other institutional investors have also recently added to or reduced their stakes in BMY. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY stock opened at $67.06 on Friday. The stock has a 50-day moving average price of $60.55 and a two-hundred day moving average price of $59.37. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The stock has a market cap of $136.98 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Analyst Ratings Changes

BMY has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Piper Sandler started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. Raymond James Financial initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Finally, Royal Bank Of Canada lifted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.